InsiderTrades

Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.

Accepted 2024-01-29 00:00:00 ET · period of report 2024-01-25 · accession 0001209191-24-002391 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-01-29 2024-01-25 RXRX Larson Tina Marriott Pres, COO M - OptEx $1.06 +8,000 422.6K +2% +$8,480
D 2024-01-29 2024-01-25 RXRX Larson Tina Marriott Pres, COO S - Sale+OE $10.35 -8,000 414.5K -2% -$82.8K
D 2024-01-29 2024-01-25 RXRX Larson Tina Marriott Pres, COO M - OptEx $0.00 -8,000 504.0K -2% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Common Stock 2024-01-25 M A 8,000 $1.06 422,584 D — —
2 Common Class A Common Stock 2024-01-25 S D 8,000 $10.35 414,548 D — — (F2) The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.17 to $10.54 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
3 Derivative Stock Option (Right to Buy) 2024-01-25 M D 8,000 $0.00 504,000 D $1.06 · — to 2028-07-22 8,000 Class A Common Stock (F4) Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.